Beatriz Wills

Hematologist/ Oncologist.Interested in CAR-T, co-host @tumortalks , global oncology.@MSKCancerCenter, @JohnsHopkinsHospital,@FSFB

[Andres Gomez @GomezDLeonMD]

Are you working on clinical-grade academic #CARTcells in LATAM?

Let's meet, say hello, and share experiences!

Comment below @LABMT2

[Yelena Y. Janjigian MD @YJanjigianMD]

That feeling when 7+ years of work lands on the front page of @NEJM—and one of the people I respect most, @KoheiShitara , writes the editorial. Honored to share this moment with you, Kohei. Here’s to a decade of friendship, and curing gastric cancer. #Matterhorn @MSKCancerCenter

[Beatriz Wills @BeatrizWills]

@virginiaabello @DrMCanales Qué honor con grandes hematólogos!

[Virginia Abello @virginiaabello]

Segunda sesión de nuestro 1 evento @Fundacion_CTIC con el aval de @achoHematoYOnco #hematologiaCTIC
Leucemia Mieloide Aguda. Con la Dra Claudia Sossa, la Dra María José López y el Dr Eytan Stein.

[Laura Korin @laura_korin]

Prognostic factors in cart cell therapy in R/R DLBCL. Yes!, I confess that I broke my own rule of not attending cart sessions until they are available in my country but it was worth it! #ICML2025 #ICML18

[John M. González @johnmgonzalez]

En Colombia siguen aumentando los casos de infección respiratoria aguda, especialmente en mayores de 60 años.
💉 La vacunación contra COVID-19, influenza y neumococo es clave para protegernos.
#SaludPública #Vacunación #Colombia

[Laura Korin @laura_korin]

Can we increase the chances of achieving CR in R/R DLBCL pts with ADCs or bispecific antibodies in combination with chemo? I think so! This is still a clinical unmet need considering lack of global cart access. Happy to have some of these trials running in 🇦🇷. #EHA25 #icml2025

[NEJM @NEJM]

Correspondence: Glofitamab with Polatuzumab Vedotin in Refractory Burkitt’s Lymphoma https://t.co/CTCS5tIyjE

#Hematology

[Beatriz Wills @BeatrizWills]

@FSFB_Salud

[Beatriz Wills @BeatrizWills]

@GomezDLeonMD wait, might be thymic rebound post IO, (need to bx if still DV 4 )common among YA, also if woman Iwould want to avoid rt to chest/ breast ca and secondary malignancy in Hl

[Lymphoma Experience @LymphomaEx]

La cuenta regresiva avanza y ya estamos a 1 mes de esta oportunidad de aprender y compartir en torno a las neoplasias linfoproliferativas.

Ven a vivir la experiencia!

#LEx25 #LExMeet25

[MSK Department of Medicine @MSK_DeptOfMed]

A phase 1 study led by @jaeparkmd evaluated a novel CAR T cell therapy for people with large B-cell #lymphoma. Of 28 trial participants, the overall response rate was 82% and complete response was 71%. Patients did well on low doses that minimized side effects. #lymsm @MSKCancerCenter
https://t.co/CGwC7tIuvr

[Guilherme Perini, MD @GuiperiniMD]

And no. 1 #PeriniPicks for #ASH24 could not be other:
https://t.co/57gexvg3Yw

"... ibrutinib+R-CHOP/R-DHAP induction followed by 2 years of ibrutinib maintenance should be the new standard of care in younger MCL patients, thus ending the era of ASCT for MCL patients"

[Beatriz Wills @BeatrizWills]

@DanilovLab @cityofhope Great talk @DanilovLab , gracias @virginiaabello , interedantes controversias!

[Danilov Lab @DanilovLab]

Looking forward to this exciting event in Bogota!

[Raul Cordoba, MD, PhD @DrRaulCordoba]

#Hematology CNS bridging #radiotherapy achieves rapid cytoreduction before #CARTcell therapy for aggressive B-cell #lymphomas | ⁦@BloodAdvances⁩ | American Society of Hematology ⁦@ASH_hematology⁩ #lymsm #radonc https://t.co/HQV90lNIIB

[Roni Shouval @RShouval]

Unexpected use of CD19-CAR-T cells: Point-of-care CD19-directed CAR-T cells in AML expressing CD19. 4/6 patients achieved a CR! @nagler_EBMT @sheba_medical #CART #AML https://t.co/1822CPMsv0

[Lymphoma Hub @lymphomahub]

CONGRESS | #SOHO2024
@gilles_salles @MSKCancerCenter discusses how to sequence therapies in R/R DLBCL, with the aim to optimize the chance of cure; concluding with a look to the future landscape and the possibility of achieving a cure amongst a substantial fraction of patients.
#lymsm #lymphoma